Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website
Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website
This is a 33.3% increase over the number of companies cited in the previous year.
The citations in the county include:
- Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.
- Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
- Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Most of the companies cited were involved in the Biologics sector.
Of the companies cited, two should take voluntary actions to correct their managing operations (50%). Additionally, two companies had to take regulatory and/or administrative actions (50%).
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Advance Medical Designs, Inc. | Devices | 06/30/2023 | Design review - Lack of or inadequate procedures |
Advance Medical Designs, Inc. | Devices | 06/30/2023 | Design history file |
Advance Medical Designs, Inc. | Devices | 06/30/2023 | Evaluation of suppliers, contractors, etc., requirements |
Advance Medical Designs, Inc. | Devices | 06/30/2023 | DMR - not or inadequately maintained |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Component identification test |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Absence of Written Procedures |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Scientifically sound laboratory controls |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Testing and release for distribution |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Adequate number of batches on stability |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Master production and control records, procedure |
MiMedx Group, Inc. | Biologics | 03/02/2023 | Strict control not exercised over labeling issued |
Reddy Naturals, LLC | Food and Cosmetics | 08/02/2023 | Master manufacturing record - each batch |